Thermal Ablation Combined With Low-dose Donafinib for Early Recurrent Hepatocellular Carcinoma: a Multicenter Prospective Study
This study intends to evaluate the efficacy and safety of low-dose adjuvant donafenib after thermal ablation for early recurrent HCC within Milan criteria.
• were aged 18-75 years;
• had recurrent HCC (RHCC) diagnosed by imaging studies, the first or the second RHCC;
• RHCC met the Milan criteria, namely single RHCC lesion less than 5 cm in diameter or no more than 3 tumors (each ≤3 cm in diameter);
• the early RHCC (recurrent time \<1 year)
• patients were unwilling to undergo repeat hepatectomy or liver transplantation;
• had well-preserved liver function, i.e., Child-Pugh class A or B, and prolonged prothrombin time≤5 s;
• patients had an Eastern Cooperative Oncology Group performance status score ≤1.
• Ability to understand the protocol and to agree to and sign a written informed consent document.